Effect of Food on the Pharmacokinetics of Piperaquine and Dihydroartemisinin

Clinical Drug Investigation

Volumn 35, Issue 9, 2015, Pages 559-567

  Reuter, Stephanie E ^a   Evans, Allan M ^a   Shakib, Sepehr ^b   Lungershausen, Yvonne ^c   Francis, Barbara ^c   Valentini, Giovanni ^d   Bacchieri, Antonella ^d   Ubben, David ^e   Pace, Silvia ^d  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b a Division of IDT Australia Ltd   (Australia)

^c BioSA Incubator   (Australia)

^d Sigma Tau SpA   (Italy)

^e Medicines for Malaria Venture   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ; PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; QUINOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALORIC INTAKE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN TRANSIT TIME; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; BIOAVAILABILITY; DIET RESTRICTION; FOOD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; BIOLOGICAL AVAILABILITY; ENERGY INTAKE; FASTING; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; MALE; QUINOLINES; YOUNG ADULT;

EID: 84941166832     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-015-0312-8     Document Type: Article

References (24)

1. World Health Organization. Guidelines for the treatment of malaria. 2015. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1. Accessed 27 July 2015.
2. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ, Nosten F. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin–piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis. 2005;41(4):425–32.
3. Myint HY, Ashley EA, Day NPJ, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin–piperaquine. Trans R Soc Trop Med Hyg. 2007;101(9):858–66.
4. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, D’Alessandro U. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg. 2006;100(12):1105–11.
5. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, Lindegårdh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ. Efficacy and effectiveness of dihydroartemisinin–piperaquine versus artesunate–mefloquine in falciparum malaria: an open-label randomised comparison. Lancet. 2006;367(95828):2075–85.
6. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong TH, Tran TT, Stepniewska K, White NJ, Farrar J. Dihydroartemisinin–piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet. 2004;363(9402):18–22.
7. Binh TQ, Ilett KF, Batty KT, Davis TM, Hung NC, Powell SM, Thu LT, Thien HV, Phuöng HL, Phuöng VD. Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Br J Clin Pharmacol. 2001;51(6):541–6.
8. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol. 2004;57(3):253–62.
9. Na-Bangchang K, Krudsood S, Silachamroon U, Molunto P, Tasanor O, Chalermrut K, Tangpukdee N, Matangkasombut O, Kano S, Looareesuwan S. The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. Southeast Asian J Trop Med Public Health. 2004;35(3):575–82.
10. Tarning J, Ashley EA, Lindegårdh N, Stepniewska K, Phaiphun L, Day NP, McGready R, Ashton M, Nosten F, White NJ. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin–piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother. 2008;52(3):1052–61.
11. European Medicines Agency. Eurartesim: piperaquine tetraphosphate/dihydroartemisinin. Product information: 28/07/2014 Eurartesim -EMEA/H/C/001199 -N/0013. 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001199/human_med_001450.jsp&mid=WC0b01ac058001d124. Accessed 5 Aug 2015.
12. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999;37(3):213–55.
13. Chinh NT, Quang NN, Thanh NX, Dai B, Travers T, Edstein MD. Short report: pharmacokinetics of the antimalarial drug piperaquine in healthy Vietnamese subjects. Am J Trop Med Hyg. 2008;79(4):620–3.
14. Sim IK, Davis TME, Ilett KF. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother. 2005;46(6):2407–11.
15. Annerberg A, Lwin KM, Lindegårdh N, Khrutsawadchai S, Ashley E, Day NPJ, Singhasivanon P, Tarning J, White NJ, Nosten N. A small amount of fat does not affect piperaquine exposure in patients with malaria. Antimicrob Agents Chemother. 2011;55(9):3971–6.
16. Hai TN, Hietala SF, Van Huong NV, Ashton M. The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop. 2008;107(2):145–9.
17. Lwin KM, Phyo AP, Hanpithakpong W, Ashley EA, Lee SJ, Cheah P, Singhasivanon P, White NJ, Lindegårdh N, Nosten F. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin–piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother. 2012;56(3):1571–7.
18. Tarning J, Lindegårdh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, White NJ, Nosten F, Day NP. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother. 2014;58(4):2052–8.
19. Dien TK, de Vries PJ, Khanh NX, Koopmans R, Binh LN, Duc DD, Kager PA, van Boxtel CJ. Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects. Antimicrob Agents Chemother. 1997;41(5):1069–72.
20. Fitoussi S, Thang C, Lesauvage E, Barré J, Charron B, Filali-Ansary A, Lameyre V. Bioavailability of a co-formulated combination of amodiaquine and artesunate under fed and fasted conditions: a randomised, open-label crossover study. Arzneimittelforschung. 2009;59(7):370–6.
21. Tan B, Naik H, Jang IJ, Yu KS, Kirsch LE, Shin CS, Craft JC, Fleckenstein L. Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malar J. 2009;8:304.
22. Tarning J, Lindegårdh N, Sandberg S, Day NJ, White NJ, Ashton M. Pharmacokinetics and metabolism of the antimalarial piperaquine after intravenous and oral single doses to the rat. J Pharm Sci. 2008;97(8):3400–10.
23. Premji ZG, Abdulla S, Ogutu B, Ndong A, Falade CO, Sagara I, Mulure N, Nwaiwu O, Kokwaro G. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether–lumefantrine: a review of the evidence. Malar J. 2008;7:244.
24. ®. Malar J. 2009;8(Suppl 1):S4.